Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OBAID SHAIKH

NPI
1184699001
CMS profile
325436
Location
PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$37.84

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $37.84 2

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $21.19 1
Aimmune Therapeutics, Inc. $16.65 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OBAID SHAIKH

NPI 1184699001 · CMS profile ID 325436

PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184699001?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OBAID SHAIKH, NPI 1184699001, CMS profile ID 325436. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184699001?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). OBAID SHAIKH, NPI 1184699001, CMS profile ID 325436. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184699001?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
OBAID SHAIKH, NPI 1184699001, CMS profile ID 325436, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1184699001?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $37.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Aimmune Therapeutics, Inc. $16.6510/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249713190 CMS
GENZYME CORPORATION $21.1909/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233397520 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $72.85 1
PY2020 $10,675.00 3
PY2021 $5,805.48 7
PY2025 $37.84 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $22,041.00 6
PY2024 Principal investigator $58,581.00 7
PY2022 Principal investigator $35,182.08 52
PY2021 Principal investigator $60,813.85 33
PY2020 Principal investigator $166,897.98 49
PY2019 Principal investigator $303,925.08 98

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $17,303.68 12/31/2020 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721317381
Principal investigator 1 Allergan, Inc. $1,273.00 12/24/2020 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721314103
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,875.00 12/17/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (FIGARO UC 302) No dispute reported 06/30/2026 737094743
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,875.00 12/17/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (AIDA) No dispute reported 06/30/2026 737094749
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $575.00 12/15/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (FIGARO UC 302) No dispute reported 06/30/2026 737094341
Principal investigator 1 Allergan, Inc. $2,000.00 12/09/2020 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721311495
Principal investigator 1 Allergan, Inc. $2,000.00 12/09/2020 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721311497
Principal investigator 1 PFIZER INC. $30,217.20 12/03/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742895793
Principal investigator 1 PFIZER INC. $670.00 12/03/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742895795
Principal investigator 1 PFIZER INC. $50.00 12/03/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742896123
Principal investigator 1 PFIZER INC. $50.00 12/03/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742896125
Principal investigator 1 PFIZER INC. $620.00 12/03/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742896891
Principal investigator 1 PFIZER INC. $17,000.00 12/02/2020 Non-covered Recipient Entity
VA Pittsburgh Healthcare System
A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF06865571 DGAT2I ALONE AND WHEN COADMINISTERED WITH PF05221304 ACCI IN ADULT PARTICIPANTS WITH BIOPSYCONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 No dispute reported 06/30/2026 742896763
Principal investigator 1 Gilead Sciences, Inc. $1,325.00 10/21/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742084959
Principal investigator 1 Allergan, Inc. $657.40 10/19/2020 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721303913
Principal investigator 1 Merit Medical Systems Inc $325.00 09/23/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer No dispute reported 06/30/2026 729615937
Principal investigator 1 Allergan, Inc. $1,324.30 09/18/2020 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721298757
Principal investigator 1 Allergan, Inc. $1,225.95 08/19/2020 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721291453
Principal investigator 1 Gilead Sciences, Inc. $1,325.00 08/19/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742084957
Principal investigator 1 Allergan, Inc. $430.00 08/07/2020 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721288937
Principal investigator 1 Gilead Sciences, Inc. $500.00 07/20/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742098733
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,886.00 07/14/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (AIDA) No dispute reported 06/30/2026 737085017
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,357.50 07/14/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (AIDA) No dispute reported 06/30/2026 737085019
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,772.00 07/14/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (AIDA) No dispute reported 06/30/2026 737085021
Principal investigator 1 Allergan, Inc. $1,000.00 07/13/2020 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721283317
Principal investigator 1 Allergan, Inc. $2,644.20 06/24/2020 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721281705
Principal investigator 1 Gilead Sciences, Inc. $818.00 06/17/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742084955
Principal investigator 1 Gilead Sciences, Inc. $2,500.00 06/10/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742098731
Principal investigator 1 Gilead Sciences, Inc. $2,500.00 05/27/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742098729
Principal investigator 1 PFIZER INC. $500.00 05/14/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742963599
Principal investigator 1 PFIZER INC. $500.00 05/07/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742963675
Principal investigator 1 PFIZER INC. $500.00 04/16/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742963671
Principal investigator 1 Merit Medical Systems Inc $325.00 03/30/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer No dispute reported 06/30/2026 729615933
Principal investigator 1 Merit Medical Systems Inc $1,950.00 03/30/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer No dispute reported 06/30/2026 729615935
Principal investigator 1 Allergan, Inc. $2,303.75 03/18/2020 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721265809
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 03/18/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 742098727
Principal investigator 1 PFIZER INC. $306.80 03/12/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742963597
Principal investigator 1 PFIZER INC. $306.80 03/05/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742963593
Principal investigator 1 Gilead Sciences, Inc. $818.00 02/24/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742084951
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 02/24/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742084953
Principal investigator 1 Allergan, Inc. $4,592.30 02/17/2020 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721258019
Principal investigator 1 PFIZER INC. $306.80 02/06/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742978419
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 02/03/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
STUDY OF THE EFFECT OF SHP647 AS MAINTENANCE TREATMENT IN PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE IN INDUCTION STUDIES No dispute reported 06/30/2026 737069069
Principal investigator 1 PFIZER INC. $306.80 01/22/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742978399
Principal investigator 1 Allergan, Inc. $25,275.70 01/20/2020 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721248719
Principal investigator 1 PFIZER INC. $306.80 01/17/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742978403
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 01/06/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742098721
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 01/06/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742098723
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 01/06/2020 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742098725